According to the results of a phase 1 clinical trial just published in STEM CELLS Translational Medicine, a new stem cell therapy shows promise of making diabetes-related amputations a thing of the past. The trial involved injecting diabetes patients suffering from non-healing diabetic foot ulcers (DFU) with a cell preparation containing adult stem cells harvested from their own fat. The results showed that the treatment induced regeneration of the blood vessels surrounding the DFUs, accelerated healing - all with no serious side effects.
Non-healing diabetic foot ulcers usually have no effective form of treatment. This work should be reviewed as it demonstrates the possibility of a novel cell injection therapy that can alleviate pain and infection, accelerate wound healing, and possibly avoid amputation."
Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and Director of the Wake Forest Institute for Regenerative Medicine
Worldwide, every 30 seconds a leg is amputated, with 85 percent caused by complications from DFU, according to estimates by the American Diabetes Association. "Peripheral vascular disease (PVD) is an aggravating condition for DFU and either alone or in combination with diabetes often culminates in recurrent, non-healing ulcers and amputations. As surgery is not always feasible for these patients, an urgent need exists for alternative therapies capable of improving blood supply to the affected foot," said Michael Carstens, M.D., of Wake Forest University's Institute of Regenerative Medicine. He and Diego Correa, M.D., Ph.D., of the University of Miami, were leaders of the study that also included researchers at the Universidad Nacional de Nicaragua-Len.
Cell-based therapies have gained attention as viable options to help restore damaged vessels while inducing the formation of new ones. Of particular interest is adipose tissue-derived stromal vascular fraction (SVF), which constitutes a collection of various cell types including adult stem cells harvested from fat tissue. The heterogeneous SVF contains endothelial progenitor cells (EPCs) and high concentrations of mesenchymal stem cells (MSCs), among other cell types. EPCs are rare cells that circulate in the blood and are present in the fat, and that give rise to the cells that make up the inner lining of blood vessels, while MSCs seat in the perivascular space surrounding blood vessels and can differentiate into a variety of cells types, depending on the conditions of the culture they are grown in. Given their intrinsic relationship with blood vessels, they cooperatively can form stable blood vessels.
"Logistical advantages complement this key multi-phenotypic display, as SVF cells can be obtained from a same-day processing of readily accessed and harvested adipose tissue, without the need of a GMP processing facility to manufacture an MSC-based product," Dr. Carstens said.
The current study builds off two previous one that the Carstens-Correa team conducted in Nicaragua to assess the value of SVF cells as an alternative and cost-effective treatment for PVD caused by arteriosclerosis and/or diabetes.
"It's difficult to treat vascular disease and chronic ulcers due to PVD and/or diabetes in resource-poor countries such as Nicaragua," Dr. Carstens said. "Patients frequently have to travel long distances under poor road conditions to obtain medical care. Revascularization procedures are not economically possible for most of the population, and advanced stem cell procedures that require cell processing facilities represent significant logistical and economic challenges. Under such conditions, non-healing ischemic wounds present patients and physicians with unpalatable choices: chronic pain and risk of infection or amputation."
Given these factors, the Ministry of Health of Nicaragua authorized their pilot study in 2014. The results from the initial 18-month follow-up period demonstrated safety of the intervention and complete wound healing by nine months. By the final six-year follow-up, five of the initial 10 subjects still demonstrated persistence of clinical benefits. (Five had passed away due to cardiac and non-study-related causes.) In the current study, the team wanted to determine the safety and efficacy of local injections of SVF cells to treat non-healing DFUs greater than 3 cm in diameter, once again working with patients in Nicaragua.
Sixty-three people ranging in age from 35 to 70 years with Type 2 diabetes and chronic DFU - all of whom were amputation candidates - were treated with SVF cells injected into the ulcer bed, around the periphery and along the course of pedal arteries (dorsalis pedis and tibialis posterior).
"SVF cells were locally administered along the vascular trajectories distally feeding the foot in an effort to concentrate the cell product around the diseased arteries, instead of the intra-muscular route used in our previous PVD study," Dr. Correa explained. "The dose of stem cells was also reduced to the lowest level tested in the earlier study in which the SVF dose ranged from 30x106 to 158x106 SVF cells. Based upon the observed clinical responses, even for the lowest dose, and taking into consideration the smaller injecting area, this time we used a fixed cell dose of 30x106 SVF cells."
Patients were seen at six- and 12-month intervals to evaluate ulcer closure. Doppler ultrasounds also were performed in a subset of patients to determine vascular structural parameters. In this group 32 of 33 pedal arteries showed increases in flow consistent with enhanced run-off due to distal neovascularization in the foot; 33/33 arteries demonstrated significant changes in arterial wall elasticity. At six months, 51 patients had 100 percent DFU closure and eight had greater than 75 percent. Three had early amputations and one patient died.
At 12 months, 50 patients had 100 percent DFU healing, while four had greater than 85 percent healing. "The healing process was observed to take place in two different directions: from the periphery, as expected, but also by upward proliferation from the ulcer bed," Dr. Carstens said. "In several cases, newly developed tissue was capable of covering previously exposed tendons. Furthermore, even among ulcers greater than 10 cm2 virtually all patients achieved 85 percent closure or better by six months. No correlation between ulcer size and closure was observed."
This led the researchers to conclude, "By using SVF injection, surgeons can prevent limb loss, an outcome with devastating socio-economic consequences for both the patient and society. The SVF protocol presented is easy to execute, can be carried out quickly and safely as an ambulatory procedure and can be done under the demanding conditions that are often experienced in the developing world."
Carstens, M.H., et al. (2021) Treatment of chronic diabetic foot ulcers with adiposederived stromal vascular fraction cell injections: Safety and evidence of efficacy at 1 year. Stem Cells Translational Medicine. doi.org/10.1002/sctm.20-0497.
- Stem Cell Therapy Market with Impact of COVID-19, Top Companies, Emerging Trends, Demand Analysis, Future Opportunity Outlook 2027 The Courier - The... - April 20th, 2021
- As scientists move closer to making part human, part animal organisms, what are the concerns? - The Conversation AU - April 20th, 2021
- Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001 in Sickle Cell... - April 20th, 2021
- bluebird bio Provides Update on Severe Genetic Disease Programs and Business Operations - StreetInsider.com - April 20th, 2021
- Shawn Vestal: A mother's journey from Honduras to Spokane 'I'm going to carry my girl' - The Spokesman-Review - April 18th, 2021
- Agenus Doses First Cancer Patient with iNKT Cell Therapy - GlobeNewswire - April 18th, 2021
- In race against COVID variants, scientists and doctors agree: The time to get vaccinated is now - Greeley Tribune - April 18th, 2021
- The Recovery Room: News beyond the pandemic April 16 - Medical News Today - April 18th, 2021
- Daily briefing: A graphical guide to vaccine benefits and risks - Nature.com - April 14th, 2021
- Stem Cell Therapy Market To Register Phenomenal Growth in the Period of 2027 The Courier - The Courier - April 14th, 2021
- Collaboration Furthers Understanding of Immune Cell Development | Newsroom - UC Merced University News - April 14th, 2021
- Biotech EryPharm Announces a Revolutionary Technological Breakthrough in the Large- Scale Manufacturing of Red Blood Cells - Business Wire - April 14th, 2021
- New Research Models Offer Promise for Understanding the Human Brain and Finding Pathways to Therapies, But Also Raise Profound Ethical Questions - The... - April 14th, 2021
- The Beljanski Foundation Launches New Website Raising Awareness on Scientific Research for Cancer and Other Chronic Diseases - PRNewswire - April 14th, 2021
- Novel Tx Helped Man With Recurrent Brain Tumor - MedPage Today - April 14th, 2021
- [Full text] Armored Car T-Cells: T-Cell Cancer Immunotherapy | BTT - Dove Medical Press - April 14th, 2021
- Insights on the Gene Therapy Cell Culture Media Global Market to 2027 - Growth in Awareness Regarding Gene Therapy is Driving Growth - Yahoo Finance - April 10th, 2021
- Dynamic Stem Cell Therapy Announces The Launch of Its Advanced Stem Cell Treatment For Knee Injury - Press Release - Digital Journal - April 10th, 2021
- Diet and the immune system: What is the link? - Medical News Today - April 10th, 2021
- Yumanity Therapeutics Announces Study Demonstrating In Vivo Efficacy of YTX-7739 in a Glioblastoma Multiforme (GBM) Mouse Model - StreetInsider.com - April 8th, 2021
- Diabetes drug could prevent brain damage in children receiving radiation for tumours: U of T study - News@UofT - April 8th, 2021
- Automated and Closed Cell Therapy Processing Systems Markets, 2030 - PRNewswire - April 8th, 2021
- Stem cell transplants offer long-term benefits for pediatric cancer patients receiving immunotherapy - News-Medical.Net - April 1st, 2021
- Bio-Techne has announced launch of Cultrex Ultimatrix BME to support organoid and pluripotent stem cell cultures - SelectScience - April 1st, 2021
- Orca-T Offers an Alternative to HSCT With Improved Patient Experience - OncLive - April 1st, 2021
- BeyondSpring Announces Submission of New Drug Application to US FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of... - April 1st, 2021
- Global Automated and Closed Cell Therapy Processing Systems Market Trends and Forecasts, 2020-2030: Cell Processing Steps, Scale of Operations, End... - April 1st, 2021
- The role of antirheumatics in patients with COVID-19 - The Lancet - April 1st, 2021
- Cultured Meat: What to Know - WebMD - March 30th, 2021
- Hydrogel used to revert cancer cells back to cancer stem cells - Drug Target Review - March 30th, 2021
- The epigenetics of aging: What the body's hands of time tell us - National Institute on Aging - March 30th, 2021
- Remarkable Turnaround Following Leronlimab Treatment in Critically Ill COVID-19 Patient After 84 days on ECMO; Case Study Published in Journal of... - March 30th, 2021
- PolarityTE Reports Fourth Quarter and Fiscal Year 2020 Results - Argus Press - March 30th, 2021
- Phase 3 Trial of Stem Cell Therapy NeuroNata-R Likely to Expand to US - ALS News Today - March 26th, 2021
- [Full text] Review of Chimeric Antigen Receptor T-cell Therapy | OTT - Dove Medical Press - March 26th, 2021
- Sorrento Announces Updated Positive Results of Phase 1b Study of COVI-MSC for Treatment of ICU COVID-19 Patients - StreetInsider.com - March 26th, 2021
- FLASH Radiotherapy: An (r)evolution in cancer treatment - Open Access Government - March 26th, 2021
- Money on the Move: March 17-23 - BioSpace - March 26th, 2021
- Stanford Researchers Find Culprit In Muscle Aging And How To Knock It Down - Bio-IT World - March 22nd, 2021
- Pivotal Phase III Study Shows Genentech's Tecentriq Helped People With Early Lung Cancer Live Longer Without Their Disease Returning - Business Wire - March 22nd, 2021
- Cell Harvesting System Market Report 2021 : Rising Impressive Business Opportunities Analysis with Top Countries Data Forecast By 2027 The Courier -... - March 22nd, 2021
- 10 Weird but Effective Anti-Aging Ingredients for Your Skin - Real Simple - March 22nd, 2021
- UK to test existing drugs as treatment for MS in world-first trial - The Guardian - March 22nd, 2021
- The Costly, Painful, Lonely Burden of Care - The New York Times - March 17th, 2021
- Taking nutrition from personalization to precision | AgriLife Today - AgriLife Today - March 17th, 2021
- When will cell-cultured meat reach price parity with conventional meat? - FoodNavigator-USA.com - March 17th, 2021
- Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020 - PRNewswire - March 13th, 2021
- Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the... - March 13th, 2021
- Bone Marrow-Derived Stem Cells (BMSCS) Market To Witness Relatively Significant Growth During Forecast to 2027 The Courier - The Courier - March 9th, 2021
- Stem Cells, The Good, The Bad and The Ugly - The Miami Project - March 7th, 2021
- 5 Proven Advantages and Disadvantages of Stem Cell ... - March 7th, 2021
- Cell Banking Outsourcing Market 2021 By Size, Key Players Profile, In-Depth Qualitative Insights, Future Plans, COVID-19 Market Outlook, Industry... - March 5th, 2021
- Dynamic Stem Cell Therapy Offers Regenerative Medicine - Las Vegas Review-Journal - March 5th, 2021
- Chemotherapy-Induced Myelosuppression Treatment Market 2021 Revenue, COVID Impact Analysis Report, I - PharmiWeb.com - March 5th, 2021
- AVROBIO Receives Orphan Drug Designation from the European Commission for AVRRD04, an Investigational Gene Therapy for Cystinosis - Business Wire - March 5th, 2021
- 5 Health Benefits of Artichokes, According to a Nutritionist - Health.com - March 5th, 2021
- Be The Match BioTherapies Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of... - March 5th, 2021
- Science on the Farm for Kids | AG | kmaland.com - KMAland - February 27th, 2021
- Stem Cell Therapy Market Analysis, Industry Outlook, Current Trends and Forecast by 2025 - Just Positivity - February 27th, 2021
- Bok Choy: Nutrition, Calories, Benefits, Risks, and How to Eat It - Healthline - February 27th, 2021
- How Will Global Stem Cell Banking Market React from 2021 Onwards? The Courier - The Courier - February 27th, 2021
- bluebird bio Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Operational Progress - Business Wire - February 27th, 2021
- Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment - BioSpace - February 27th, 2021
- 4 Health Benefits of Cranberry Juice (Plus 4 Cranberry Juice Recipes to Try) - PureWow - February 27th, 2021
- Poseida Therapeutics Provides Update on Key Programs and Developments During R&D Day - PRNewswire - February 27th, 2021
- Combine Fasting & Holistic Health With This Four-Week Program - mindbodygreen.com - February 23rd, 2021
- Can I Get the COVID-19 Vaccine If I Have Cancer? - Health Essentials from Cleveland Clinic - February 23rd, 2021
- Chemotherapy-Induced Myelosuppression Treatment Market is Poised to Exhibit A Moderate 3.2% CAGR by - PharmiWeb.com - February 23rd, 2021
- Gene Panel Market Is Estimated to Reach USD 4.34 Billion by 2025 at CAGR of 12.16% | Market Research Future (MRFR) - GlobeNewswire - February 23rd, 2021
- Interview: Tanya Siddiqi, MD, Discusses the Promise of Reduced Toxicity With Liso-Cel - AJMC.com Managed Markets Network - February 21st, 2021
- Key Trends in Hematopoietic Stem Cells Transplantation Industry Impacting the Global Market with Forecast 2021-2026 NeighborWebSJ - NeighborWebSJ - February 21st, 2021
- White Fungus: Benefits, Uses, and What to Know - Healthline - February 21st, 2021
- bluebird bio 'baffled' after NICE rejects beta-thalassaemia gene therapy - - pharmaphorum - February 19th, 2021
- 3D bioprinting paves way for functional adult-sized tissues and organs - News-Medical.Net - February 19th, 2021
- Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation... - February 14th, 2021
- Stem Cell Manufacturing Market Improvement Status (2021-2027) By Analyzing the Performance of Various Competitors: Thermo Fisher Scientific, Merck... - February 14th, 2021
- Orchard Therapeutics talks the benefits of HSC therapy - BioProcess Insider - February 12th, 2021
- Using 3D Printing to Develop Bone-Like Structures that Contain Living Cells - AZoM - February 12th, 2021
- Zebrafish reveal regenerative protein that could inspire new treatments for muscle-wasting diseases and aging - FierceBiotech - February 12th, 2021
- The race to treat a rare, fatal syndrome may help others with common disorders like diabetes - Science Magazine - February 12th, 2021